Stability differences between condition 1 and other conditions across participants on the non-hemiparetic side (NHP) side. by Hyung Suk Yang (20442438)

Subjects:

Transition probabilities and class sizes for three-step LTA model (N = 432). by Carolin Oetzmann (11397968)

Subjects:

Algorithm operation steps. by Junyan Wang (4738518)

Subjects:

Demonstration of test steps. by Jin Zhu (164147)

Subjects:

Increase in physical activity (100 step, 500 steps or 1000 steps) after the challenge according to decrease in screen time < or ≥60 minutes. by Annaëlle Le Steunf (19838110)

Stability differences between condition 1 and other conditions across participants on the hemiparetic (HP) side. by Hyung Suk Yang (20442438)

Subjects:

Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque count. by Francesca Catto (21253435)

“…Additionally, the plots on the right side display the average plaque count across the cohorts. …”

Summary of five key points guiding the Safe Steps evaluation and implementation. by Esario IV Daguman (21474116)

Subjects:

The influence of the controlled pH conditions at the sample preparation step on the obtained signals (panel A: extraction using a mixture of MeOH and EtOH; panel B: extraction usin... by Ewa Paszkowska (21246702)

Subjects:

Schematic for preparation steps of BRA and recycled asphalt. by Ying Fang (147352)

Subjects:

Simulations show that microSLAM improves power and false positive rates. by Miriam Goldman (21433180)

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects:

Schematic representation of the study protocol. by Neng Pan (5262032)

Subjects: